Navigation Links
Osteo Science Foundation to Support Scientific and Clinical Research in Oral and Maxillofacial Surgery

ROSEMONT, Ill., Oct. 21, 2013 /PRNewswire-USNewswire/ -- Dr. Peter Geistlich, chairman of the board of Geistlich Pharma, has established the Osteo Science Foundation to advance hard and soft tissue regeneration in the area of oral, cranial and maxillofacial surgery through high quality basic and clinical research, and education that leads to improved outcomes and quality of life for patients.


Creation of the Osteo Science Foundation was announced at the OMS Faculty Section Business Meeting convened during the 2013 AAOMS Annual Meeting in Orlando, FL, October 7-12. Dr. Jay P. Malmquist, Chairman of the Foundation Board, states that, "Advancements in regenerative medicine are continuously improving clinical outcomes in the area of oral, cranial and maxillofacial surgery. The Osteo Science Foundation seeks to maximize these advancements by supporting scientific and clinical research and education relating to the most effective surgical techniques and clinical use of biomaterials and biologics."

In pursuit of its objective to encourage scientific and clinical research in the area of regenerative medicine, the Osteo Science Foundation has initiated a call for abstracts with a submission deadline of December 1, 2013. The first grants are expected to be awarded in July 2014, with funding of up to $50,000 per project and a maximum duration of two years. Dr. Malmquist noted that there is no proscribed cap on the number of projects that may be accepted for the grants. He further stated that by 2015, the number of grant cycles will be increased to two per year, and the first educational symposium will be held.

"AAOMS is excited to work with the Osteo Science Foundation to encourage research in the area of hard and soft tissue regeneration in the oral, cranio and maxillofacial surgical area," said AAOMS President Dr. Miro A. Pavelka. "Biomaterials and biologics hold tremendous promise for the treatment we provide our patients. This is truly the future of oral and maxillofacial surgery in the United States."

Joining Dr. Malmquist on the Osteo Science Foundation Board are oral and maxillofacial surgeons Dr. Alan S. Herford, chairman and program director of the Department of OMS Residency Program at Loma Linda University School of Dentistry, and Dr. Peter K. Moy, professor, Department of Oral and Maxillofacial Surgery, UCLA School of Dentistry.

Saving Face | Changing Lives® — The American Association of Oral and Maxillofacial Surgeons (AAOMS), the professional organization representing more than 9,000 oral and maxillofacial surgeons in the United States, supports its fellows' and members' ability to practice their specialty through education, research and advocacy. AAOMS fellows and members comply with rigorous continuing education requirements and submit to periodic office anesthesia evaluations.

For further information check the AAOMS Website at

SOURCE American Association of Oral & Maxillofacial Surgeons
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
2. Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
3. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
4. Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth
5. RNL BIO Co. Ltd. Files IND To Commence Phase II Clinical Trial Of RNL-JointStem For Osteoarthritis In The United States
6. Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee
7. Musculoskeletal Network covers the Osteoarthritis Research Society International Conference
8. Nearly 30 Percent of Women Fail to Pick Up New Prescriptions for Osteoporosis, Kaiser Permanente Study Finds
9. Nuovi dati rivelano il crescente problema dellosteoporosi in Europa
10. PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
11. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
Post Your Comments:
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  InCarda ... the development and commercialization of therapies for cardiovascular conditions ... established a subsidiary business in Australia ... clinical trial in Australia in ... with leading investigators and medical centers in ...
(Date:12/1/2015)... and TELTOW, Germany , December ... (SMI) , a leading global manufacturer of eye and ... has included SMI remote eye trackers as a ... healthcare providers assess concussions, eye sight, and medical and ... -oem technology is part of SMI,s mass-market-ready eye tracking ...
(Date:12/1/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... 2016 as the ex-distribution date for Ampio,s previously announced ... Stock of Aytu BioScience, Inc. As announced, Ampio will ... every five (5) shares of Ampio Common Stock owned ... date will be January 4, 2016. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic ... addition to the devices for sale in the United States. Clarity is a ... 1064 nm Nd:YAG lasers, into a single platform that is easy to own and ...
(Date:12/1/2015)... ... ... With FCPX Overlay: Grit , users can apply a grit effect ... truly endless, all with a click of a mouse. Each user has full control ... of field and more, all within Final Cut Pro X. , With FCPX Overlay: ...
(Date:11/30/2015)... India (PRWEB) , ... November 30, 2015 , ... ... dental search engine optimization companies, announced today that it has officially launched a ... Third Molar SEO, explained that his company’s new website clearly outlines the benefits ...
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. ... in the MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was ... a BMI of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight ...
Breaking Medicine News(10 mins):